Sight Sciences, Inc. (SGHT)
| Previous close | 21.92 |
| Open | 22.00 |
| Bid | 20.20 x 900 |
| Ask | 22.11 x 800 |
| Day's range | 21.00 - 22.01 |
| 52-week range | 17.36 - 42.57 |
| Volume | 134,523 |
| Avg. volume | 249,517 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 43.67 |
- GlobeNewswire
Sight Sciences to Participate in the Upcoming Piper Sandler Annual Healthcare Conference
MENLO PARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced plans to participate in the upcoming Piper Sandler Annual Virtual Healthcare Conference. A recording of the fireside chat will be available beginning on Monday, November 22, 2021, at 10:00am ET. Interested parties may access the webcast on the “Investor
- GlobeNewswire
Microinvasive Glaucoma Surgery with the OMNI® Surgical System is Associated with Diminished Diurnal IOP Fluctuations, a Significant, Independent Risk Factor for Glaucoma Progression
12-Month OMNI data from the prospective, multicenter GEMINI clinical trial show statistically significant postoperative reductions in mean IOP and suppression of daily IOP fluctuationsMENLO PARK, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced publication in Clinical Ophthalmology of favorable data showing that
- Motley Fool
Sight Sciences, Inc. (SGHT) Q3 2021 Earnings Call Transcript
SGHT earnings call for the period ending September 30, 2021.
